Connect your AI

Exelixis EXEL Other income, net (Note 6)

Other income, net (Note 6) at other companies

Ionis PharmaceuticalsIONS

-$456K-198%

PfizerPFE

——

IncyteINCY

——

BridgeBio PharmaBBIO

——

ALN

Alnylam PharmaceuticalsALNY

——

Royalty PharmaRPRX

——

Other financials

Income statement

Revenue$610.8M+10.0%

Gross profit$590.9M+10.2%

Operating income$251.3M+34.5%

Net income$210.5M+31.9%

EPS (diluted)$0.79+43.6%

Balance sheet

Cash & equivalents$226.2M+23.1%

Total debt$169.5M-9.4%

Total equity$1.9B-9.2%

Total assets$2.6B-8.6%

Cash flow

Operating cash flow$251.8M+19.1%

CapEx$1.5M-48.9%

Free cash flow$250.3M+20.1%

Valuation

Market cap$13.05B+10.1%

Enterprise value$12.99B+9.5%

P/E15.7×-2.8×

P/S5.5×+0.3×

Profitability

Gross margin96.4%-0.3pp

Operating margin39.4%+6.3pp

Net margin35.1%+7.1pp

FCF margin38.6%+2.9pp

Returns & leverage

Return on equity41%+10.8pp

Debt / equity0.1×0.0×

Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Exelixis's other income, net (note 6)?: Exelixis (EXEL) reported other income, net (note 6) of $219K in Q1 2026.
How has Exelixis's other income, net (note 6) changed year-over-year?: Exelixis's other income, net (note 6) increased by 189.4% year-over-year, from -$245K to $219K.